
Although the trial includes multiple tumor types, the presented data focus on RCC, predominantly clear cell disease.
Ayanambakkam is an assistant professor of hematology oncology and an adjunct assistant professor of urology, associate program director of the OUHSC Hematology Oncology Fellowship Program, medical director of the Genitourinary Medical Oncology Research & SCC Infusion Center at Stephenson Cancer Center, University of Oklahoma Health Sciences Center.